Overview

Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section

Status:
Completed
Trial end date:
2002-02-01
Target enrollment:
Participant gender:
Summary
Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section. We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.
Phase:
Phase 2
Details
Lead Sponsor:
Basel Women’s University Hospital
University Hospital, Basel, Switzerland
Treatments:
Misoprostol
Oxytocin